{
  "docId": "019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "docSlug": "86e21d9d1e23",
  "documentTitle": "PMV Pharmaceuticals (PMVP)",
  "authorId": "60_Wolfpack_Research",
  "authorName": "Wolfpack Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-05-19 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 14,
  "pageCount": 19,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a pipeline chart to visually demonstrate the lack of progress in the mentioned programs.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "process_diagram",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-8c03a48e7d6f/14",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-8c03a48e7d6f#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.038,
        "w": 0.766,
        "x": 0.117,
        "y": 0.211
      },
      "kind": "callout",
      "text": "We expect to advance our next program, targeting the p53 R273H hotspot mutation, into lead optimization in the first half of 2021.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a28a5a7-6889-4bc9-9d5f-8f399bddc847",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "This delay in advancing additional hotspot mutation programs and the shift in strategy to focus on alternate pathways to improve wild-type p53 activity can only be seen as an additional red flag.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a679-a823cfc05ede",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.278,
        "w": 0.766,
        "x": 0.117,
        "y": 0.323
      },
      "kind": "chart",
      "text": "Pipeline chart showing status of PC14586 and other undisclosed programs.",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f448846-879d-4575-98f3-416e4f6edc66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.766,
        "x": 0.117,
        "y": 0.644
      },
      "kind": "paragraph",
      "text": "We believe the most likely explanation for this delay is a lack of encouraging signs seen from the ongoing Phase 1/2 study with PC14586, and since these two drugs are very similar to the lead candidate, these drugs in all probability are a bust.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "328f2d09-bbc8-4800-bf71-77e077fa2f5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.766,
        "x": 0.117,
        "y": 0.133
      },
      "kind": "paragraph",
      "text": "When PMV Pharma filed the Form S/1 (September 2020), the company noted two additional programs beyond PC14586... The S/1 suggested that the program targeting R273H was moving into lead optimization in the first half of 2021.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65fd6606-2256-476a-96de-4900a2050e09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.766,
        "x": 0.117,
        "y": 0.258
      },
      "kind": "paragraph",
      "text": "However, as of the most recent Investor Presentation (and Pipeline chart shown on the company’s website), neither the R273H nor the 282W programs show candidates in lead optimization.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66cffdea-2dab-4864-857f-6773d1d8991c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.766,
        "x": 0.117,
        "y": 0.712
      },
      "kind": "paragraph",
      "text": "Instead PMV has moved a new drug candidate into pole position, one that targets WIP1... This is a completely different mechanism of action and strategy from targeting hotspot mutations such as Y220C, R273H, and/or R282W.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6babc8ed-b1bd-4388-81ff-c5f1e6d34231",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.766,
        "x": 0.117,
        "y": 0.811
      },
      "kind": "paragraph",
      "text": "This delay in advancing additional hotspot mutation programs and the shift in strategy to focus on alternate pathways to improve wild-type p53 activity can only be seen as an additional red flag.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "799c70bd-7988-425b-9797-367e4561bff6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "We expect to advance our next program, targeting the p53 R273H hotspot mutation, into lead optimization in the first half of 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-70f9-71ae-a679-ae160775f8e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.15,
        "x": 0.117,
        "y": 0.895
      },
      "kind": "source-note",
      "text": "PMVP, S1, 134, 9/4/2020",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a89e37a-5ef8-430f-aab9-eb69930802f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.688,
        "x": 0.117,
        "y": 0.093
      },
      "kind": "title",
      "text": "PMV’s Management Is Already Moving on to a New Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8597a4f-dac5-4bcc-834f-5e3927c8e866",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "100506b3-f452-4c91-b41e-17bebaef57fb",
      "evidence": "The slide explicitly contrasts past management guidance with current pipeline status to argue for a hidden failure.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 13,
      "beatId": "b60b9bcc-c14b-47d9-9883-5ca559055bcc",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "The document highlights the struggles PMV Pharma may face with its drug candidate.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}